A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction: The aim of this study was to evaluate the safety, pharmacokinetics, and clinical response of brodalumab (AMG 827), a human, anti-IL-17 receptor A (IL-17RA) monoclonal antibody in subjects with moderate-to-severe rheumatoid arthritis (RA). Methods: This phase Ib, randomized, placebo-controlled, double-blind multiple ascending dose study enrolled subjects with moderate to severe RA (≥6/66 swollen and ≥8/68 tender joints). Subjects were randomized 3:1 to receive brodalumab (50 mg, 140 mg, or 210 mg subcutaneously every two weeks for 6 doses per group; or 420 mg or 700 mg intravenously every 4 weeks for two doses per group) or placebo. Endpoints included incidence of adverse events (AEs) and pharmacokinetics. Exploratory endpoints included pharmacodynamics, and improvements in RA clinical metrics. Results: Forty subjects were randomized to investigational product; one subject discontinued due to worsening of RA (placebo). The study was not designed to assess efficacy. AEs were reported by 70% (7/10) of placebo subjects and 77% (22/30) of brodalumab subjects. Three serious AEs were reported in two subjects; there were no opportunistic infections. Brodalumab treatment resulted in inhibition of IL-17 receptor signaling and receptor occupancy on circulating leukocytes. No treatment effects were observed with individual measures of RA disease activity. On day 85 (week 13) 37% (11/30) of brodalumab subjects and 22% (2/9) of placebo subjects achieved ACR20; 7% (2/30) brodalumab subjects and 11% (1/9) of placebo subjects achieved ACR50; and 0% (0/30) brodalumab subjects and 0% (0/9) of placebo subjects achieved ACR70. Conclusions: Multiple dose administration of brodalumab was tolerated in subjects with active RA. There was no evidence of a clinical response to brodalumab in subjects with RA. Trial registration: ClinicalTrials.gov, NCT00771030
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 1×
“Aberrant Th17 responses and IL-17 production have been implicated in a variety of human autoimmune diseases, including psoriasis, RA, psoriatic arthritis (PsA) and multiple sclerosis [6,7].”
BackgroundInterleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409 · cited 2×
“The role of IL-17 in the pathogenesis of RA has been studied in both preclinical and clinical studies [5].”
BackgroundHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., & Maslinski, W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2832 · Cited by 580 · cited 1×
“Increased levels of IL-17A have been detected in the synovial fluid of patients with RA [8-10], and blockade of IL-17A signaling can inhibit osteoclast formation induced by conditioned culture media of RA synovial tissues.”
BackgroundPavelka, K., Chon, Y., Newmark, R., Lin, S.-L., Baumgartner, S., & Erondu, N. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141271 · Cited by 83
Cited by
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
The IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Interleukin-17 and innate immunity in infections and chronic inflammation
Isailovic, N., Daigo, K., Mantovani, A., & Selmi, C. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.006 · Cited by 363
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637829 · Cited by 360
Targeting Th17 cells in autoimmune diseases
Yang, J., Sundrud, M. S., Skepner, J., & Yamagata, T. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.006 · Cited by 348
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Selected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 303
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Fasching, P., Stradner, M., Graninger, W., Dejaco, C., & Fessler, J. (2017) · Molecules · doi:10.3390/molecules22010134 · Cited by 254
Berry, S. P. D.-G., Dossou, C., Kashif, A., Sharifinejad, N., Azizi, G., Hamedifar, H., Sabzvari, A., & Zian, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108402 · Cited by 124
Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis
Miyazaki, Y., Nakayamada, S., Kubo, S., Nakano, K., Iwata, S., Miyagawa, I., Ma, X., Trimova, G., Sakata, K., & Tanaka, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02901 · Cited by 87
Metadata
- Authors
- Martin, D. A., Churchill, M., Flores-Suarez, L. F., Cardiel, M. H., Wallace, D., Martin, R., Phillips, K., Kaine, J. L., Dong, H., Salinger, D., Stevens, E., Russell, C. B., & Chung, J. B.
- Venue
- Arthritis Research & Therapy
- Published
- 2013-10-25
- Volume
- 15
- Issue
- 5
- Pages
- R164-R164
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2107583569
- Cited by
- 107
- References
- 7
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.